Bluebird bio CFO Transition
This article was originally published in Scrip
Bluebird Bio, Inc., a company developing therapies for genetic diseases and cancer, has appointed Jeffrey Walsh chief financial and strategy officer – effective March 1, 2016. Current chief financial officer, Jim DeTore, has decided to leave the company – effective March 18, 2016. Since 2011 Walsh was chief operating officer at bluebird bio and prior to joining the company, he was chief business officer at Taligen Therapeutics. He has held senior business development, finance and operations roles at PathoGenesis Corp., AllScripts Healthcare Solutions, EXACT Sciences and Inotek Pharmaceuticals.
Register for our free email digests: